10.1002/chem.201904822
Chemistry - A European Journal
COMMUNICATION
12 mol%), o-xylene (2 mL), i-Pr2NEt (52.3 μL, 0.3 mmol, 1.5 eq), and
phenyl acetylene (28.6 μL, 0.26 mmol, 1.3 eq) in that order at room
temperature. This mixture was allowed to stir for 30 minutes. The vial was
purged with dry N2 and then cooled to –78 ºC. TBSOTf (60 μL, 0.26 mmol,
1.3 eq) was added at –78 ºC, then the reaction was transferred to the lab
freezer at –28 ºC and allowed to react for 48h. The reaction was quenched
by the addition of 6N HCl (2 mL) and stirred for 2 hours. The reaction
mixture was extracted with EtOAc (3 x 2 mL), washed with saturated
NaHCO3 solution, dried over anhydrous NaSO4, and the solvent removed
under vacuum to obtain the crude product. The crude product was purified
by column chromatography on silica gel with Hexane:EtOAc (9:1) to afford
an off white solid (48.8 mg, 98% yield, 97 %ee).
valuable in the context of naturally occurring tetrahydroxanthone
synthesis by enabling the enantioselective construction of tertiary
ether stereocenters. The reaction was put to the test with the
addition of phenyl acetylene to chromone-2-carboxylate esters
(Table 3). We were delighted to find an initial enantiomeric excess
of 34% with the bis(oxazoline) ligand 5a containing a benzyl group
(R = Bn, entry 1). A quick screen of other readily available
bis(oxazoline) ligands resulted in the identification of t-Bu as the
best substituent identified to date with respect to both the yield
and enantiomeric excess (entry 3). Upon cooling the reaction from
0°C to –28°C a very encouraging 67% enantiomeric excess was
observed (entry 4). Ethyl, i-propyl, and t-butyl chromone-2-
carboxylate esters were also tolerated but with reduced
enantiomeric excess (entries 5-7).
Acknowledgements
Table 3. Tertiary ether stereocenter formation
The National Institutes of Health are gratefully acknowledged for
providing funds for our studies (5 R35 GM124804).
Keywords: Asymmetric Catalysis • Heterocycles • Synthetic
Methods • Natural Products • Synthetic Design
[1]
For recent reviews on dimeric chromanones and tetrahydroxanthones,
see: a) T. Wezeman, S. Brase, K. Masters Nat. Prod. Rep. 2015, 32, 6-
28; b) K. Masters, S. Brase, Chem. Rev. 2012, 112, 3717-3776. For
isolation and biological activities of gontyolides, see: H. Kikuchi, M. Isobe,
M. Sekiya, Y. Abe, T. Hoshikawa, K. Ueda, S. Kurata,Y. Katou, Y,
Oshima Org. Lett. 2011, 13, 4624-4627. For isolation and biological
activities of phomoxanthone A, see: a) M. Isaka, A. Jaturapat, K.
Rukserre, K. Damwisetkanjana, M. Tanticharoen, Y. Thebtaranonth J.
Nat. Prod. 2001, 64, 1015-1018; b) D. Ronsberg, A. Debbab, A. Mandi,
V. Vasylyeva, P. Bohler, B. Stork, L. Engelke, A. Hamcher, R. Sawadogo,
M. Diederich, V. Wray, W. Lin M. Kassack, C. Janiak, S. Scheu, S.
Wesselborg, T. Kurtan, A. Aly, P. Proksch J. Org. Chem. 2013, 78,
12409-12425. For isolation and biological activities of the blennolides,
see: W. Zhang, K. Krohn, Zia-Ullah, U. Florke, G. Pescitelli, L. Di Bari, S.
Antus, T. Kurtan, J. Rheinheimer, S. Draeger, B. Schulz Chem. Eur. J.
2008, 14, 4913-4923. For isolation and biological data on the
dicerandrols, see: M. M. Wagenaar and J. Clardy J. Nat. Prod. 2001, 64,
1006-1009.
Entry[a]
Ligand
R’ =
R =
Temp.
°C
Yield
(%)
ee
(%)
1[b]
2[b]
3[b]
4
Bn (5a)
Ph (5b)
Me
Me
Me
Me
Et
0
29
86
87
87
91
88
15
34
15
0
t-Bu (5d)
t-Bu (5d)
t-Bu (5d)
t-Bu (5d)
t-Bu (5d)
0
-38
-67
-65
-54
-60
–78 to – 28
–78 to – 28
–78 to – 28
–78 to – 28
5
5
i-Pr
t-Bu
7
[a] See Supporting Information for detailed procedures. [b] Conducted in a two-
step process in toluene, see procedure 1 in the supporting information for
details.
[2]
For a review, see: A. E. Nibbs.; K. A. Scheidt Eur. J. Org. Chem. 2012,
2012, 449−462. For select examples of enantioselective 2-
alkylchromanone synthesis, see: (a) A. V. Rao, A. S. Gaitonde, S. P.
Prakash, S. P. Rao Tetrahedron Lett. 1994, 35, 6347−6350. (b) M.
Kawasaki, H. Kakuda, M. Goto, S. Kawabata, T. Kometani Tetrahedron:
Asymmetry 2003, 14, 1529−1534; (c) M. M. Biddle, M. Lin, K. A. Scheidt
J. Am. Chem. Soc. 2007, 129, 3830−3831; (d) H. Boekl, R. Mackert, C.
Muramann, N. Schweickert US66646136B1, 2013; (e) A. O. Termath, H.
Sebode, W. Schlundt, R. T. Stemmler, T. Netscher, W. Bonrath, H.-G.
Schmalz Chem. - Eur. J. 2014, 20, 12051−12055; (f) M. K. Brown, S. J.
Degrado, A. H. Hoveyda Angew. Chem. Int. Ed. 2005, 44, 5306-5310;
(g) C. Vila, V. Hornillos, M. Fananas-Mastral, B. L. Feringa Chem.
Commun. 2013, 49, 5933-5935; (g) B. M. Trost, E. Gnanamani, C. A.
Kalnmals, C.-I. Hung, J. S. Tracy J. Am. Chem. Soc. 2019, 141, 1489-
1493.
In conclusion, copper bis(oxazoline) complexes have proven
to be easy to use, general catalyst systems for the synthesis of 2-
stereogenic centers found in biologically relevant chromanones.
Excellent levels of enantiocontrol can be achieved in the reaction
of a diverse array of chromenone and alkyne reaction partners,
generating desirable 2-ethynyl chromanone products in high yield.
The reaction system can also be extended to the synthesis of
more highly substituted 2-stereogenic centers that may have
direct applications in naturally occurring bioactive chromanone
and tetrahydroxanthone synthesis. Our current efforts, directed
toward the continued exploration of these reactions in the
synthesis of naturally occurring dimeric tetrahydroxanthones, will
be reported as soon as possible.
[3]
[4]
[5]
(a) T. Qin, T. Iwata, T. T. Ransom, J. A. Beutler, J. A. Porco J. Am. Chem.
Soc. 2015, 137, 15225-15233; (b) T. Qin, J. A. Porco Angew. Chem. Int.
Ed. 2014, 53, 3107-3110.
(a) L. F. Tietze, L. Ma, J. R. Reiner, S. Jackenkroll, S. Heidemann Chem.
Eur. J. 2013, 19, 8610-8614; (b) D. Ganapathy, J. R. Reiner, G. Valdomir,
S. Senthilkumar, L. F. Tietze Chem. Eur. J. 2017, 23, 2299-2302.
For select work on the generation and reactions of benzopyrylium triflates,
see: (a) H. Iwasaki, T. Kume, Y. Yamamoto, K. Akiba Tetrahedron Lett.
1987, 28, 6355-6358; (b) L. A. Stubbing, F. F. Li., D. P. Furkert, V. E.
Experimental Section
To an 8 mL screw top vial was added chromone (29.2 mg, 0.2 mmol, 1.0
eq), CuI (3.8 mg, 0.02 mmol, 10 mol%), (S)-Bn-BOX (8.8 mg, 0.024 mmol,
This article is protected by copyright. All rights reserved.